收入端：FY2026 中期公司营业收入167 亿元，同比增长17%，主要受益于商品收入的较快增长。分拆看，1）报告期内公司医药自营收入143亿元，同比增长19%，主要由于自营B2C 零售商品的SKU 供给不断丰富，同比增长99%至161 万，处方药中原研药等类目高速增长，越来越多药企把电商作为新药首发的渠道，此外国补带来的医疗器械增长主要集中在自营部分；2）电商平台服务收入18 亿元，同比增长8%...
Source Link收入端：FY2026 中期公司营业收入167 亿元，同比增长17%，主要受益于商品收入的较快增长。分拆看，1）报告期内公司医药自营收入143亿元，同比增长19%，主要由于自营B2C 零售商品的SKU 供给不断丰富，同比增长99%至161 万，处方药中原研药等类目高速增长，越来越多药企把电商作为新药首发的渠道，此外国补带来的医疗器械增长主要集中在自营部分；2）电商平台服务收入18 亿元，同比增长8%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.